Sort   by:  
 Page size 
UnknownA Trial of a Single-tablet Regimen of Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Disoproxil Fumarate for the Initial Treatment of Human Immunodeficiency Virus Type 2 Infection in a Resource-limited Setting: 48-Week Results From Senegal, West Africa.
Not available
S-EPMC6927863 | biostudies-literature
Unknown{1-[1-(2-Hy-droxy-phen-yl)ethyl-idene]-2-(pyridin-2-yl-κN)hydrazine-κ2N',O}{1-[1-(2-oxidophen-yl)ethyl-idene]-2-(pyridin-2-yl-κN)hydrazine-κ2N',O}nickelate(II) nitrate hemihydrate.
Not available
S-EPMC5947478 | biostudies-literature
UnknownThree main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: implications for emerging HIV-2 treatment regimens.
Not available
S-EPMC3445448 | biostudies-literature
UnknownHIV-1 outcompetes HIV-2 in dually infected Senegalese individuals with low CD4⁺ cell counts.
Not available
S-EPMC4043222 | biostudies-literature
UnknownLong-term Experience and Outcomes of Programmatic Antiretroviral Therapy for Human Immunodeficiency Virus Type 2 Infection in Senegal, West Africa.
Not available
S-EPMC7850514 | biostudies-literature
UnknownBroad and potent neutralizing antibody responses elicited in natural HIV-2 infection.
Not available
S-EPMC3255805 | biostudies-literature
UnknownPreoperative mortality risk evaluation in abdominal surgical emergencies: development and internal validation of the NDAR score from a national multicenter audit in Senegal.
Not available
S-EPMC11515558 | biostudies-literature
Sort   by:  
 Page size